Advertisement

Basic Research in Cardiology

, Volume 80, Issue 2, pp 135–141 | Cite as

Ischemia aggravating effects of platelet-activating factor in acute myocardial ischemia

  • I. Leprán
  • A. M. Lefer
Original Contributions

Summary

The effect of platelet-activating factor (PAF) was studied during the acute phase of myocardial ischemia in cats. PAF infusion (0.75 μg/kg/h for 4.5 h) in anesthetized, open-chest cat decreased arterial blood pressure, but did not influence heart rate or biochemical indices of cell integrity. The same dose of PAF, however, started 30 min after coronary ligation, resulted in a significantly higher elevation of plasma creatine phosphokinase (CK) activity and a reduced CK content in the region of the ischemic myocardium. Treatment with the thromboxane A2 synthetase inhibitor, CGS-13080, significantly attenuated the PAF-aggravated ischemic cellular damage. These experiments suggest that hypoxiagenerated PAF may contribute to the aggravation of myocardial ischemia, part of which appears to be due to PAF-induced release of thromboxane A2.

Key words

coronary artery occlusion thromboxane synthetase inhibitor ST segment elevation creatine kinase activity arterial blood pressure 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Benveniste J, Henson PM, Cochrane CG (1972) Leukocyte-dependent histamine release from rabbit platelets: the role of IgE-basophils and platelet-activating factor. J Exp Med 136:1356PubMedGoogle Scholar
  2. 2.
    Benveniste J, Roubin R, Chignard M, Jouvin-Marche E, LeCouedic JP (1982) Release of platelet-activating factor (PAF-acether) and 2-lyso-PAF-acether from three cell types. Agents and Actions 12:711PubMedGoogle Scholar
  3. 3.
    Benveniste J, Boullet C, Brink C, Labat C (1983) The actions of PAF-acether (platelet-activating factor) on guinea-pig isolated heart preparation. Br J Pharmacol 80:81PubMedGoogle Scholar
  4. 4.
    Bjork J, Lindbrom L, Gerdin B, Smedegard G, Arfors KE, Benveniste J (1983) PAF-acether (platelet-activating factor) increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds. Acta Physiol Scand 119:305PubMedGoogle Scholar
  5. 5.
    Blank ML, Snyder F, Byers LW, Brooks B, Muirhead EE (1979) Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem Biophys Res Comm 90:1194PubMedGoogle Scholar
  6. 6.
    Burke SE, DiCola G, Lefer AM (1983) Protection of ischemic cat myocardium by CGS-13080, a selective potent thromboxane A2 synthesis inhibitor. J Cardiovasc Pharmacol 5:842PubMedGoogle Scholar
  7. 7.
    Chignard M, LeCouedic JP, Tence M, Vargaftig BB, Benveniste J (1979) The role of platelet-activating factor in platelet aggregation. Nature 279:799PubMedGoogle Scholar
  8. 8.
    Chignard M, Wal F, Lefort J, Vargaftig BB (1982) Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea-pig. Eur J Pharmacol 78:71PubMedGoogle Scholar
  9. 9.
    Coker SJ, Ledingham IMcA, Parratt JR, Zeitlin IJ (1981) Aspirin inhibits the early myocardial release of thromboxane B2 and ventricular ectopic activity following acute coronary artery occlusion in dogs. Br J Pharmacol 72:593PubMedGoogle Scholar
  10. 10.
    Gorman RR, Morton DR, Hopkins NK, Lin AH (1983) Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis and cyclic AMP accumulation in human polymorphonuclear leukocytes. In: Samuelsson B, Paoletti R, Ramwell P (eds). Adv Prostaglandin, Thromboxane, Leukotriene Res Vol 12. Raven Press, New York, p 57Google Scholar
  11. 11.
    Lefer AM, Ogletree ML, Smith JB, Silver MJ, Nicolaou KC, Barnette WE, Gasic GP (1978) Prostacyclin: A potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science 200:52PubMedGoogle Scholar
  12. 12.
    Lefer AM, Polansky EW (1979) Beneficial effects of ibuprofen in acute myocardial ischemia. Cardiology 69:265Google Scholar
  13. 13.
    Lefer AM, Smith III EF, Araki H, Smith JB, Aharony D, Claremon DA, Magolda RL, Nicolaou KC (1980) Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proc Natl Acad Sci USA 7:1706Google Scholar
  14. 14.
    Lefer AM, Smith JB, Müller HF (1984) Pathophysiologic mechanisms of sudden death induced by platelet-activating factor (PAF). (In Press, Br J Pharmacol)Google Scholar
  15. 15.
    Leprán I, Koltai M, Szekeres L (1981) Effect of nonsteroid anti-inflammatory drugs in experimental myocardial infarction in rats. Eur J Pharmacol 69:235PubMedGoogle Scholar
  16. 16.
    McManus LH, Hanahan DJ, Demopoulos CA, Pinckard RN (1980) Pathobiology of intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit. J Immunol 124:2919PubMedGoogle Scholar
  17. 17.
    Myers A, Ramey E, Ramwell P (1983) Glucocorticoid protection against PAF-acether toxicity in mice. Br J Pharmacol 79:595PubMedGoogle Scholar
  18. 18.
    O'Flaherty JT, Wykle RL, Miller CH, Lewis JC, Waite M, Bass DA, McCall CE, DeChatelet LR (1981) 1-0-alkyl-sn-glyceryl-3-phosphorylcholines: a novel class of neutrophil stimulants. Am J Pathol 103:70PubMedGoogle Scholar
  19. 19.
    Ogletree ML, Lefer AM (1976) Influence of nonsteroidal anti-inflammatory agents on myocardial ischemia. J Pharmacol Exp Therap 197:582Google Scholar
  20. 20.
    Prevost MC, Cariven C, Simon MF, Chap H, Douste-Blazy L (1984) Platelet activating factor (PAF-acether) is released into rat pulmonary alveolar fluid as a consequence of hypoxia. Biochem Biophys Res Commun 119:58PubMedGoogle Scholar
  21. 21.
    Rosalki SB (1967) Improved procedure for creatine phosphokinase determination. J Lab Clin Med 69:696PubMedGoogle Scholar
  22. 22.
    Smith III EF, Lefer AM, Aharony D, Smith JB, Magolda RL, Claremon D, Nicolaou KC (1981) Carbocyclic thromboxane A2: Aggravation of myocardial ischemia by a new synthetic thromboxane A2 analog. Prostaglandins 21:443PubMedGoogle Scholar
  23. 23.
    Smith JB, Burke SE, Lefer AM, Freilich A (1984) Continuous measurements of ATP secretion in vivo. Pharmaceut Res 1:40Google Scholar
  24. 24.
    Vargaftig BB, Lefort J, Chignard M, Benveniste J (1980) Platelet activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Europ J Pharmacol 65:185Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag 1985

Authors and Affiliations

  • I. Leprán
    • 1
  • A. M. Lefer
    • 1
  1. 1.Department of Physiology, Ischemia-Shock Research Center, Jefferson Medical CollegeThomas Jefferson UniversityPhiladelphia(U.S.A.)

Personalised recommendations